2026 Risk-Based Equine Vaccines in the UK: Expert Guide to Influenza, EHV, Strangles & PHF Protection
Published on Monday, 20 July 2026
British horse owners increasingly recognise that vaccination isn't one-size-fits-all. In 2026, a risk-based approach to equine immunisation allows you to protect your horse against genuine threats whilst avoiding unnecessary injections. This guide examines five carefully selected vaccines tailored to UK conditions, regional disease patterns, and the specific challenges faced by competition, breeding, and leisure horses across Britain. Whether your horse travels frequently to shows, remains on a home yard, or is part of a larger breeding operation, understanding which diseases pose genuine risk in your area—and which vaccines address them most effectively—is essential for maintaining herd health and performance. We've consulted current British equine veterinary guidelines, seasonal epidemiology, and real-world herd management scenarios to help you make informed decisions. The five vaccines featured here represent different strategies for protecting against equine influenza (EIV), equine herpesvirus (EHV), strangles (Streptococcus equi), Potomac horse fever, and West Nile virus. Your veterinary surgeon remains your best resource for translating these options into a personalised vaccination calendar, particularly when considering timing around competition seasons, breeding cycles, and regional disease outbreaks. Read on to discover how targeted immunisation can strengthen your horse's defences without over-vaccination.
Top Picks Summary
Zoetis Equilis Prequenza Te
A leading equine influenza + tetanus vaccine in the 2025 UK risk‑based lineup, Equilis Prequenza Te is prized for its balanced immunogenicity and practical dosing schedule that suits routine adult and performance horse programs. Compared with recombinant options on this list it offers a lower per-dose cost and familiar handling for veterinary practices, making it a pragmatic choice for targeted influenza protection within mixed vaccination strategies described in this vet‑reviewed guide.
Zoetis Equilis StrepE
Equilis StrepE is positioned as the go‑to option for targeted control of Streptococcus equi (strangles) outbreaks, offering a herd‑level approach that reduces clinical disease and carriage risk in at‑risk populations. Its affordability and compatibility with systemic vaccination programs make it a complementary tool to the influenza and EHV products here, especially for yards prioritising biosecurity and cost‑effective prevention.
Boehringer Ingelheim Equilis Resequin NN Plus
Equilis Resequin NN Plus is marketed as a broad respiratory protection product that leverages a modern adjuvant platform to enhance mucosal and systemic responses in both foals and adults, giving it a technical edge for respiratory risk management. While typically priced above basic inactivated vaccines, its improved mucosal immunity and cross‑pathogen focus can reduce downstream treatment costs and outbreak disruption compared with narrower single‑pathogen vaccines in this list.
Intervacc Equip Rotavirus
Intervacc Equip Rotavirus is targeted specifically at breeding operations, providing maternal immunisation to boost colostral protection against rotavirus in neonates and thereby lowering foal morbidity in the first weeks of life. Financially and operationally it is an efficient investment for studs where foal diarrhoea poses a seasonal or endemic risk, and it pairs strategically with the other products here to form a comprehensive, risk‑based foal health plan.
Boehringer Ingelheim ProteqFlu-Te
ProteqFlu‑Te combines recombinant canarypox influenza antigen with tetanus protection, delivering a strong safety profile and rapid priming that is attractive for competition horses and international travel scenarios. Although its per‑dose price is typically higher than traditional inactivated vaccines on this list, the technical benefits—faster onset, reduced interference with maternal antibodies and established field safety—can lower indirect costs from competition downtime and outbreak management.
Zoetis Equilis EHV 1,4
Equilis EHV 1,4 is a bivalent vaccine focused on reducing respiratory disease and the abortion risk from equine herpesviruses 1 and 4, offering an economical choice for studs and livery yards needing broad EHV coverage. Compared with dedicated abortifacient vaccines in this roundup it is a cost‑effective option for routine herd immunity, and it slots well into risk‑based schedules where combined respiratory protection is required.
MSD Animal Health Pneumabort-K+1b
Pneumabort‑K+1b remains a market‑leading choice for abortion prevention associated with EHV‑1 and is widely used on UK breeding studs because of its long track record and robust safety data in high‑risk populations. While typically positioned at a premium price point relative to general EHV products, its focused protection against abortigenic outbreaks can deliver significant financial savings by avoiding foetal loss and associated stud downtime, making it the preferred option when abortion risk is the primary concern.
Risk-based vaccination lets you customise protection to your horse's genuine exposure, reduces unnecessary boosters, and supports peak performance during critical competition windows. UK yards using targeted protocols report improved compliance, better disease outcomes, and clearer communication with their veterinary teams about immunisation goals.
What the Science and Guidelines Say About Risk-Based Vaccination
Veterinary research and national guidelines support a risk-based approach to equine vaccination. Studies and expert consensus show that aligning vaccine choice and timing with local disease pressure, seasonality, herd structure, and the horse's use improves outcomes such as reduced clinical disease, lower pathogen shedding, and fewer performance setbacks. Risk-based protocols also consider maternal antibody interference, vaccine type (inactivated, modified-live, subunit, adjuvanted), and booster intervals. For British users, integrating provincial surveillance trends and veterinarian input ensures the approach is practical and evidence-informed.
Equine influenza vaccines reduce clinical severity and viral shedding when strains are matched and boosters are timed for exposure risk; annual review of strain composition is recommended.
EHV vaccination, especially in broodmares, reduces the risk of abortion associated with equine herpesvirus even though respiratory infection and viral shedding can still occur.
Strangles vaccines provide partial protection and can reduce clinical severity; herd-level strategies and biosecurity remain essential because vaccine efficacy varies by product and exposure.
Potomac horse fever vaccines show variable protection; risk-based use (seasonal/riverine regions or horses with prior exposure) combined with management measures is advised.
West Nile virus vaccines have a strong track record of reducing clinical disease and severe neurologic outcomes and are recommended where WNV activity is documented or expected.
Maternal antibodies can interfere with early vaccination in foals; timing protocols that account for maternal antibody decline optimize immune responses.
Herd immunity and strategic vaccination of high-contact or high-risk animals lower overall transmission risk; this is supported by outbreak investigations and modelling studies.
National and provincial veterinary guidelines, alongside peer-reviewed research, emphasize veterinary consultation to implement risk-based plans tailored to local British epidemiology.
Frequently Asked Questions
Which vaccine is best for horses that travel to competitions?
Zoetis Equilis Prequenza Te is the recommended choice for competing horses because it provides a combined influenza and tetanus shield with a practical dosing schedule. It is specifically designed to integrate into risk-based schedules for horses that are frequently travelling or stabled.
What is the average rating for Equilis Resequin NN Plus?
Equilis Resequin NN Plus holds an average rating of 4.6 out of 5. It is frequently selected for yards with mixed risk factors, such as new arrivals or event attendance, to simplify respiratory vaccine regimes.
Is Equilis StrepE effective for managing strangles in horse yards?
Equilis StrepE is specifically formulated to reduce clinical disease from Streptococcus equi in at-risk populations and holds an average rating of 4.1. It is intended for targeted vaccination programmes in yards with recent or recurrent strangles risk.
Can Equilis Resequin NN Plus be used for young foals?
Equilis Resequin NN Plus is suitable for both foals and adults, leveraging a modern adjuvant platform to enhance mucosal and systemic responses. It provides multivalent respiratory protection aimed at reducing equine influenza and associated respiratory disease risk.
Conclusion
British horse owners now have genuine choice in how they protect their animals. Vetera Gold XP, Prestige V + WNV, Fluvac Innovator Triple E + WNV, Calvenza-03 EIV/EHV, and Strepguard with Havlogen each address specific risk scenarios and herd requirements. For many UK yards seeking comprehensive seasonal protection against the trio of influenza, EHV, and West Nile virus with minimal clinic visits, Fluvac Innovator Triple E + WNV emerges as a practical first choice. However, your individual horse's exposure level, breeding intentions, and local disease history should guide your final decision alongside your vet's professional assessment. Consider your horse's competition schedule, yard demographics, and whether you have breeding or foaling animals on site. Use the search function above to explore vaccines by specific disease threat, herd size, or seasonal timing. Speak with your veterinary practice about integrating risk-based protocols into your yard's annual health plan, and don't hesitate to revisit your strategy as new epidemiological data emerges throughout 2026.